ABAC Therapeutics develops targeted antibiotics that specifically combat severe bacterial infections resistant to standard treatments. By utilizing advanced drug design techniques, the company aims to improve patient outcomes and reduce the duration of hospital stays for affected individuals.
Funding
$20M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Severe bacterial infections are increasingly resistant to standard antibiotic treatments, leading to longer hospital stays and poorer patient outcomes. Current broad-spectrum antibiotics can also harm beneficial bacteria, disrupting the microbiome and potentially leading to secondary infections.
Solution
ABAC Therapeutics develops targeted antibiotics designed to selectively combat severe bacterial infections while minimizing disruption to the patient's microbiome. The company utilizes advanced drug design techniques to create novel compounds that specifically target resistant bacteria, improving patient outcomes and reducing the duration of hospital stays. By focusing on precision targeting, ABAC Therapeutics aims to overcome the limitations of traditional broad-spectrum antibiotics and address the growing threat of antimicrobial resistance.
Target Audience
The primary target audience includes hospitals, healthcare providers, and patients suffering from severe bacterial infections resistant to standard antibiotic treatments.
Features
- Advanced drug design for targeted bacterial eradication
- Compounds designed to minimize disruption to the microbiome
- Focus on severe bacterial infections resistant to standard treatments